In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required procedures.
Subjects likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge
Ability to attend all scheduled study visits
Patients who cannot comply with protocol requirements including clinic visits for intravenous infusions and birth control measures may not be enrolled.
Patients must be willing to receive follow-up care for a minimum of five years after treatment at the treating institution, including annual follow up visits; in the event that the patient is not from the local area and returning to the treating institution for follow up visits is too difficult, they must be willing to have their outside medical information (i.e. imaging studies, laboratory results and doctor or other health professional notes) released to the treating institution to track the results of treatment
Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up.
In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
Willing to travel to the NIH for follow-up visits
Inability to attend scheduled clinic visits
Willing and able to provide a signed and dated informed consent, comply with the study plan, follow up visits and phone calls
In the investigators judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation
Willing to travel to the National Institutes of Health (NIH) for follow-up visits
Resident in the area and willing to attend up to  clinic visits for a -month period at the Virology Research Clinic (VRC)
Unavailable for follow-up visits after treatment
Subject likely to not be available to complete all protocol required study visits or procedures to the best of the subject and investigator's knowledge
Patients must be willing to travel to the study site for follow-up visits
Subject is willing and able to comply with all protocol required visits and assessments.
Willing to travel to the National Institutes of Health (NIH) for follow-up visits
Ability to understand and willingness for follow-up visits.
Agree to attend study visits outside of standard of care visits, if needed
The subject is willing and able to comply with the protocol, and agrees to return to the hospital for follow?up visits and examination
Unwilling to alter or remove hairstyle, hair extensions, or wig during the clinic visits to allow for correct electroencephalography (EEG) sensor placement
Able to attend all study visits (i.e., life expectancy of at least  months).
Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned.
Patients who are able and willing to give consent and able to attend all study visits
Able to attend all study visits (i.e. life expectancy of at least  months).
Must be able and willing to adhere to protocol requirements, visits and vaccination timeline
 Subjects likely to not be available to complete all protocol- required study visits or procedures including BM aspirates/biopsies, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
Willing to travel to the National Institutes of Health (NIH) for follow-up visits
The patient must be accessible for scheduled visits, treatment and follow-up. Patients registered on this trial must be treated at the participating center which could be the Principal or a Co- investigator's site.
Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge.
Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned to the MTD expansion cohort;
Patient is willing and able to give consent and attend all study visits as defined in the protocol
Ability and agreement to attend protocol-specified visits at the study site
Willing to travel to the NIH, MSKCC, DFCI, BIDMC for follow-up visits
Patients must be willing to travel to the study site for follow-up visits
Willing and able to participate in clinic visits and study interactions at specified intervals and to maintain contact with the investigators for at least three months
Ability and willingness to follow the guidelines of the clinical protocol including visits to National Institute of Child Health and Human Development (NICHD) and NCI, Bethesda, Maryland for treatment and follow up visits
Able to adhere to the study visit schedule (ie, clinic visits at the study sites are mandatory, unless noted otherwise for particular study visits) and other protocol requirements.
Willing to travel to the NIH for follow-up visits
Willing and able to adhere to the protocol requirements, including but not limited to study drug dosing, study drug visits, medication and treatment restrictions, and laboratory tests
Subject agrees to comply with follow up visits
signed informed consent for the HIFU treatment study through the  month follow-up visit ( visits) and then through the extended follow-up period of  years ( additional visits);
No social support or inability to attend study-related visits
Patients (or guardians/parents) who are able and willing to give consent (and assent where applicable) and able to attend all study visits
Ability to understand and the willingness to sign a written informed consent document and follow the guidelines of the clinical protocol including visits to National Cancer Institute (NCI), Bethesda, Maryland for treatment and follow up visits
Anticipated non-availability for study visits/procedures
Anticipated non-availability for study visits/procedures.
Ability and willingness to follow the guidelines of the clinical protocol including visits to NCI, Bethesda, Maryland for treatment and follow up visits
Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits.
Patients who are able and willing to give consent and able to attend all study visits
 Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
Individuals that are unwilling or unable to attend study visits or are planning to move out of a study site coverage area during the subjects anticipated participation in the study
Have outpatient visits at least once a month
Subject agrees to comply with follow-up procedures, including returning for all follow-up visits
Transportation issues interfering with return study visits
Must be able to comply with follow up visits
Willing and able to attend study visits at the University of Wisconsin (UW)  Madison
SUBJECT: History of medical non-compliance or difficulty completing previous required study tasks or visits that suggest the participants would not follow through with the home study procedures.
Subject is willing and able to meet study requirements, including follow up visits
Are willing and able to attend  study visits at the University of Wisconsin (UW)
Availability of a reliable parent or legal guardian who is willing and able to complete all of the outcome measures and fulfill the requirements of the study, including administration of medications and accompanying the participant to all study visits
Have visits planned with the oncology physician for at least  months and be willing to come in for study visits
Any participant who cannot be present for the related study visits and/or complete the post-test assessment
Unavailable for follow-up visits
Willing to travel to MD Andersons main campus for  visits (baseline and  months post-baseline)
The subject is able to complete the study and comply with study instructions, including attending all study visits
Inability to complete all study-related visits
Is willing and able to comply with study instructions and commit to all clinic visits for the duration of the study
Willing to attend monthly clinic visits at University of California, San Francisco (UCSF)
Planned relocation which would make follow-up visits impossible during the course of the study
Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up.
Subject is willing and able to provide written informed consent. . Subject is willing and able to meet all study requirements, including follow-up visits and receiving study-related telephone calls.
Subject is willing and able to comply with all protocol required visits and assessments;
Investigator has concerns regarding the ability of the subject to give written informed consent and/or to comply with study procedures (including availability for follow up visits).
Subject agrees to comply with the study requirements and agrees to come to the clinic for required study visits
PHASE I: MGUH patients presenting for well visits, and patients' parents
Willing to complete all study visits
Geographically able to have study visits at the University of California, Los Angeles (UCLA) Clinical Research Unit
Are geographically able to have study visits at UCLAs Warren Hall or the Clinical Translational Research Center
Willing to take NRT for up to  months, and be willing to complete  follow-up telephone-based counseling sessions and  follow-up visits
Patient is willing and able to give consent attend all study visits and complete all questionnaires as defined in the protocol
Ability to attend clinic visits
Willing to complete all study visits
Must be willing to attend all scheduled study visits, complete all study questionnaires, and allow biological specimen collection including a bronchoscopy within - months after enrollment into the study
Willingness to travel to National Institutes of Health (NIH) for follow-up visits
Patients must be willing and able to be compliant with all procedures and visits required for this protocol (pre-treatment, during treatment, and optionally throughout follow-up period)
Able to understand, follow written instruction and willing to participate in all visits without rescheduled more than one or missed a visit without cancellation or rescheduling (no show)
Willingness to travel to National Institutes of Health (NIH) for follow-up visits
Willing and able to participate in clinic visits, group sessions, and telephone and Internet communications at specified intervals
Willingness to travel to National Institutes of Health (NIH) for follow-up visits
Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
